Clinical Benefit within Patient Subgroups Receiving c7E3 Fab (Abciximab) During Percutaneous Coronary Revascularization: Subgroup Analysis from the EPIC Trial.
Academic Article
Overview
publication date
- January 1, 1996
published in
Identity
PubMed ID
- 10785766
Additional Document Info
volume
- 8 Suppl B